Giuseppe Banna: Selpercatinib for RET fusion+ NSCLC by Benjamin Besse et al.
A recent paper by Benjamin Besse, Director of Clinical Research at the Gustave Roussy Institute, published in JCO Oncology Advances, was mentioned by Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, on X:
“Selpercatinib for RET fusion-positive NSCLC: Continuing treatment beyond progression shows promise, especially for oligo and CNS PD. Median post-PD ToT: 9.8 months for oligoPD. Local Radiotherapy boosts outcomes.”
“Selpercatinib Treatment Beyond Progression in RET Fusion–Positive Non–Small Cell Lung Cancer”
Authors: Benjamin Besse, Maria de Miguel, Yu Jung Kim, Melissa Johnson, Jason Chan, Patrick Peterson, Sylwia Szymczak, Tarun Puri, Geoffrey Oxnard, Daniel Tan.
More posts featuring Giuseppe Banna and Benjamin Besse.
Giuseppe Banna is a Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust and the Candiolo Cancer Institute IRCCS. He leads the Translational Research and Clinical Trials Unit for Thoracic Tumors.
Additionally, he serves as an Honorary Teacher Practitioner at the Universities of Nottingham and Lincoln, and is affiliated with United Lincolnshire Hospitals NHS Trust.
Benjamin Besse is the Head of Clinical Research at Gustave Roussy and a Full Professor of Medical Oncology at University of Paris-Saclay. He serves as the Chair of the Scientific Council at EORTC and is the Coordinator of RYTHMIC, the French thymic malignancies network.0
His research is centered on personalized therapeutic strategies, focusing on molecular abnormalities, circulating biomarkers, and early drug development for thymic malignancies and thoracic tumors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023